Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244569 · ClinicalTrials.gov registry record · Phase 3
Development of a Breath Test for Monitoring Patients With Liver Disease
A Phase 3 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00244569 is a Phase 3 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 120 participants.
The verdict
NCT00244569, a Phase 3 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.
Interventions
- DRUG 13C-Methacetin
- DEVICE Breath ID Machine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244569
The ClinicalTrials.gov registry entry for NCT00244569 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 13C-Methacetin is the first listed.
NCT00244569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244569 about?
NCT00244569 is a clinical study titled "Development of a Breath Test for Monitoring Patients With Liver Disease". The purpose of this study is to determine the safety and efficacy of the Oridion Breath ID machine in monitoring liver metabolic functions.
What is the current status of trial NCT00244569?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2005-09. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00244569?
The interventions under investigation include: 13C-Methacetin (DRUG), Breath ID Machine (DEVICE).
Who is sponsoring clinical trial NCT00244569?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.